Articles

Delirium Symptoms More Severe in Patients Treated with Antipsychotics

Adult hospice and palliative care patients with hyperactive delirium symptoms who were given risperidone or haloperidol had greater delirium symptoms at 72 hours than those given placebo.

Transitioning from Inpatient to Outpatient Chemotherapy Saves Money, Increases Patient Satisfaction

By Meg Barbor, MPH

Conference Correspondent

TOP - February 2017, Vol 10, No 1

Inpatient chemotherapy is often considered a financial loss, and according to Ali McBride, PharmD, MS, BCPS, BCOP, Clinical Coordinator, Hematology/Oncology, The University of Arizona Cancer Center, Tucson, transitioning chemotherapy to the outpatient setting can be beneficial to patients and providers.

Mounting Evidence for Ki67 as Independent Prognostic Marker

By Alice Goodman

Breast Cancer

TOP - February 2017, Vol 10, No 1

Several studies have shown that Ki67 is an independent prognostic factor in patients with breast cancer, and Ki67 is included in the Oncotype DX test that estimates the likelihood of breast cancer recurrence and the need for chemotherapy.

FDA News & Updates, In the News

Web Exclusives

The FDA has granted accelerated approval of rucaparib (Rubraca), a poly ADP-ribose polymerase inhibitor, for the treatment of patients with advanced ovarian cancer whose tumors have deleterious BRCA gene mutation and have been treated with ≥2 chemotherapies. The administration also approved a companion diagnostic to the drug, FoundationFocus CDxBRCA, which is the first next-generation sequencing diagnostic test.

Real-World Experience with Taiho Oncology Patient Support for Lonsurf® (trifluridine and tipiracil)

By Lisa A. Raedler, PhD, RPh, Medical Writer

Patient Assistance Profiler December 2016

As the costs associated with cancer care continue to escalate, all key stakeholders—healthcare providers, private and government payers, and patients—strive to balance high-quality cancer care with cost efficiency. As insurance benefit designs continue to shift the cost burden of treatment, more patients with cancer and their families are both psychologically and financially invested in treatment decisions.

By Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Updates

Web Exclusives

In April 2016, venetoclax (Venclexta; Janssen) became the first BCL-2 inhibitor to be approved by the FDA for relapsed, high-risk chronic lymphocytic leukemia.

FDA News & Updates, In the News

Web Exclusives

The FDA has granted approval to daratumumab (Darzalex) for the treatment of patients with multiple myeloma who have received ≥1 previous therapies, in combination with dexamethasone and either lenalidomide or bortezomib.

By Meg Barbor, MPH

Conference Correspondent

Web Exclusives

Chicago, IL—The anaplastic lymphoma kinase (ALK) mutation is a target for tyrosine kinase therapies in several cancers, including non–small-cell lung cancer (NSCLC). Since 2011, several ALK inhibitors have been approved, and more are in the pipeline, but many questions remain for managing patients with ALK-positive NSCLC.

By Meg Barbor, MPH

Web Exclusives

Chicago, IL—Maintaining a clean room compliant with US Pharmacopeial Convention Chapter 800 (USP 800) can come with a significant price tag, but noncompliance can drive up costs to oncology practices and institutions. However, certain measures can contribute to the successful construction, renovation, and maintenance of hazardous drug sterile compounding spaces in an oncology setting, according to Ryan A. Forrey, PharmD, MS, FASHP, Director of Pharmacy, Emory University Hospital Midtown, Atlanta, GA.

Conference Correspondent

Web Exclusives

Chicago, IL—A clear set of standard operating procedures is at the heart of US Pharmacopeial Convention Chapter 800 (USP 800) compliance, according to Carol Yarrington, PharmD, BCOP, Oncology and Infusion Pharmacy Coordinator and Clinical Oncology Pharmacist, St. Joseph Mercy Health System, Ann Arbor, MI.

Articles

Page 119 of 289